Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad
- PMID: 17572303
- DOI: 10.1016/j.bbcan.2007.05.001
Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad
Abstract
Chromosome 20q13 is highly amplified in human cancers, including 20-30% of early stage human breast cancers. The amplification correlates with poor prognosis. Over-expression of the zinc-finger protein 217 (ZNF217), a candidate oncogene on 20q13.2, in cultured human mammary and ovarian epithelial cells can lead to their immortalization, indicating that selection for ZNF217 expression may drive 20q13 amplification during critical early stages of cancer progression. ZNF217 can also attenuate apoptotic signals resulting from exposure to doxorubicin, suggesting that ZNF217 expression may also be involved in resistance to chemotherapy. Recent findings indicate that ZNF217 binds specific DNA sequences, recruits the co-repressor C-terminal binding protein (CtBP), and represses the transcription of a variety of genes. Inappropriate expression of ZNF217 may lead to aberrant down-regulation of genes involved in limiting the proliferation, survival, and/or invasiveness of cancer cells. Better understanding of ZNF217 and its associated pathways may provide new targets for therapeutic intervention in human cancers.
Similar articles
-
Silencing of ZNF217 gene influences the biological behavior of a human ovarian cancer cell line.Int J Oncol. 2008 May;32(5):1065-71. Int J Oncol. 2008. PMID: 18425333
-
ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction.Hum Mol Genet. 2005 Nov 1;14(21):3219-25. doi: 10.1093/hmg/ddi352. Epub 2005 Oct 3. Hum Mol Genet. 2005. PMID: 16203743
-
The candidate oncogene ZNF217 is frequently amplified in colon cancer.J Pathol. 2004 Nov;204(3):282-8. doi: 10.1002/path.1632. J Pathol. 2004. PMID: 15476264
-
The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value.Oncotarget. 2015 Dec 8;6(39):41566-81. doi: 10.18632/oncotarget.5893. Oncotarget. 2015. PMID: 26431164 Free PMC article. Review.
-
Oncogene amplification in neoplastic development and progression of human cancers.Crit Rev Oncog. 1990;2(1):35-51. Crit Rev Oncog. 1990. PMID: 2091749 Review.
Cited by
-
Competing Endogenous RNA Networks as Biomarkers in Neurodegenerative Diseases.Int J Mol Sci. 2020 Dec 16;21(24):9582. doi: 10.3390/ijms21249582. Int J Mol Sci. 2020. PMID: 33339180 Free PMC article. Review.
-
The Intricate Interplay between the ZNF217 Oncogene and Epigenetic Processes Shapes Tumor Progression.Cancers (Basel). 2022 Dec 8;14(24):6043. doi: 10.3390/cancers14246043. Cancers (Basel). 2022. PMID: 36551531 Free PMC article. Review.
-
Molecular Insight Into the Therapeutic Potential of Long Non-coding RNA-Associated Competing Endogenous RNA Axes in Alzheimer's Disease: A Systematic Scoping Review.Front Aging Neurosci. 2021 Nov 25;13:742242. doi: 10.3389/fnagi.2021.742242. eCollection 2021. Front Aging Neurosci. 2021. PMID: 34899268 Free PMC article.
-
Plasma Circular RNAs as Biomarkers for Breast Cancer.Biomedicines. 2024 Apr 16;12(4):875. doi: 10.3390/biomedicines12040875. Biomedicines. 2024. PMID: 38672229 Free PMC article. Review.
-
ZNF217/ZFP217 Meets Chromatin and RNA.Trends Biochem Sci. 2016 Dec;41(12):986-988. doi: 10.1016/j.tibs.2016.07.013. Epub 2016 Aug 9. Trends Biochem Sci. 2016. PMID: 27519282 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials